相似文献
1
Have Your Sodium-Glucose Cotransporter 2 Inhibitor-Derived Ketones and Eat Them Too.拥有源自钠-葡萄糖协同转运蛋白2抑制剂的酮体并食用它们。
JACC Basic Transl Sci. 2025 Mar;10(3):304-306. doi: 10.1016/j.jacbts.2024.12.013.
2
Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.钠-葡萄糖共转运蛋白 2 抑制剂可诱导重症心力衰竭患者心外膜脂肪组织的抗炎和抗铁死亡转化。
Cardiovasc Diabetol. 2024 Jun 28;23(1):223. doi: 10.1186/s12933-024-02298-9.
3
Sodium-glucose cotransporter-2 inhibitor use in patients with a Fontan circulation.钠-葡萄糖协同转运蛋白2抑制剂在接受Fontan循环手术患者中的应用
Cardiol Young. 2025 Apr;35(4):745-747. doi: 10.1017/S1047951125000514. Epub 2025 Feb 26.
4
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.达格列净对射血分数降低的心力衰竭影响的代谢组学分析：DEFINE-HF 研究。
Circulation. 2022 Sep 13;146(11):808-818. doi: 10.1161/CIRCULATIONAHA.122.060402. Epub 2022 May 23.
5
Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction.钠-葡萄糖共转运蛋白 2 抑制剂对射血分数降低的心力衰竭患者营养状况的影响。
Rev Assoc Med Bras (1992). 2022 Nov 28;68(11):1576-1581. doi: 10.1590/1806-9282.20220737. eCollection 2022.
6
Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.钠-葡萄糖协同转运蛋白2抑制剂在射血分数保留的心力衰竭管理中的潜力：一项叙述性综述
Cureus. 2024 Nov 18;16(11):e73906. doi: 10.7759/cureus.73906. eCollection 2024 Nov.
7
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.探究钠-葡萄糖协同转运蛋白2抑制剂以及钠-葡萄糖协同转运蛋白1/钠-葡萄糖协同转运蛋白2双重抑制剂在心力衰竭治疗中的地位：文献系统综述
Heart Fail Rev. 2024 Mar;29(2):549-558. doi: 10.1007/s10741-024-10388-9. Epub 2024 Feb 1.
8
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.钠葡萄糖协同转运蛋白2抑制剂恩格列净可独立于钠葡萄糖协同转运蛋白2减少梗死面积。
Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688.
9
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
10
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update.糖尿病合并心力衰竭患者的钠-葡萄糖协同转运蛋白2抑制剂：最新进展
Pharmaceuticals (Basel). 2024 Oct 23;17(11):1419. doi: 10.3390/ph17111419.
本文引用的文献
1
Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF.在射血分数降低的心力衰竭（HFrEF）中，通过背景钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗对酮酯进行代谢和药代动力学分析。
JACC Basic Transl Sci. 2025 Mar;10(3):290-303. doi: 10.1016/j.jacbts.2024.10.014. Epub 2024 Nov 15.
2
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净对射血分数不同心衰患者的代谢影响
Circ Heart Fail. 2024 Nov;17(11):e011980. doi: 10.1161/CIRCHEARTFAILURE.124.011980. Epub 2024 Oct 18.
3
Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.口服酮酯治疗射血分数降低的心力衰竭患者的心血管效应：一项随机、对照、双盲试验。
Circulation. 2024 May 7;149(19):1474-1489. doi: 10.1161/CIRCULATIONAHA.123.067971. Epub 2024 Mar 27.
4
Retained Metabolic Flexibility of the Failing Human Heart.衰竭人类心脏的代谢灵活性得以保留。
Circulation. 2023 Jul 11;148(2):109-123. doi: 10.1161/CIRCULATIONAHA.122.062166. Epub 2023 May 18.
5
Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭的心肌代谢组学。
Circulation. 2023 Apr 11;147(15):1147-1161. doi: 10.1161/CIRCULATIONAHA.122.061846. Epub 2023 Mar 1.
6
Comprehensive quantification of fuel use by the failing and nonfailing human heart.全面量化衰竭和非衰竭人心肌的燃料利用。
Science. 2020 Oct 16;370(6514):364-368. doi: 10.1126/science.abc8861.
7
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.恩格列净通过增强心肌能量代谢改善非糖尿病心力衰竭的不良左心室重构。
J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056.
8
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.治疗慢性心力衰竭患者酮体 3-羟丁酸的心血管效应。
Circulation. 2019 Apr 30;139(18):2129-2141. doi: 10.1161/CIRCULATIONAHA.118.036459.
9
Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes.营养性酮症改变燃料偏好，从而提高运动员的耐力表现。
Cell Metab. 2016 Aug 9;24(2):256-68. doi: 10.1016/j.cmet.2016.07.010. Epub 2016 Jul 27.
Zotero 插件